Oxbow Advisors’s Exact Sciences EXAS Stock Holding History

Oxbow Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,000	Closed	-$134K	–	253
2016 Q4	$134K	Hold	10,000	–	–	0.02%	243
2016 Q3	$186K	Hold	10,000	–	–	0.03%	231
2016 Q2	$122K	Hold	10,000	–	–	0.02%	246
2016 Q1	$67K	Hold	10,000	–	–	0.01%	250
2015 Q4	$92K	Buy	+10,000	New	+$93K	0.01%	259

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oxbow Advisors's EXAS Position: Q1 2017 in Review

Oxbow Advisors sold out of Exact Sciences (EXAS) in Q1 2017, closing a stake of 10,000 shares — an estimated $134K sold.

Oxbow Advisors first reported a position in EXAS in Q4 2015 and held it in 5 quarters. The position peaked at $186K in Q3 2016. 224 funds tracked by Wall St. Rank hold EXAS as of Q1 2017.

Oxbow Advisors reported no remaining Exact Sciences position as of Q1 2017 after selling out during the quarter.
Oxbow Advisors sold 10,000 Exact Sciences shares in Q1 2017, an estimated $134K.
Oxbow Advisors first reported a position in Exact Sciences in Q4 2015 and held it in 5 quarters.
Oxbow Advisors's Exact Sciences position peaked at $186K in Q3 2016.
224 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2017.

Based on Oxbow Advisors's 13F filing for Q1 2017, filed 28 Apr 2017.